MetaGuideX is a diagnostic research company that has developed an accurate, fast, non-invasive diagnostic for predicting metastasis (spread of cancer cells) with high specificity and sensitivity. With this tool, they aim to redefine the cancer care pathway. The tool is designed to be used alongside existing standard investigation methods to reduce the need for lymph node biopsies, saving the patient from unneeded procedures and the NHS money.
Find your nearest AHSN
MetaGuideX want their cancer biomarker to reduce healthcare spend and prevent life-long pain for patients. They want to empower clinicians to reduce the time of diagnosis of cancer and provide better patient outcomes in line with NHS Long Term Plan. MetaGuideX needed to refine their business plan to secure further investment to make this ambition a reality.
We were confident that MetaGuideX had a diagnostic product that could improve the lives of women with breast cancer, but we were not sure of the best way to place it into the healthcare system. The Oxford AHSN Accelerator took us on an exciting and challenging journey to explore the current healthcare landscape. Thanks to the accelerator programme, we now have a better set of tools and a clear strategy on how best to position our diagnostic to maximise the benefit to both patients and their clinicians.
Dr Ryan Pink, CEO at MetaGuideX
How did the Innovation Exchange help?
The Oxford AHSN Accelerator programme, in collaboration with BioCity and regional partners from the NHS, industry and research within the Thames Valley, offers a launchpad for entrepreneurs and their ventures to move from idea to market. MetaGuideX won a place on the intensive eight-week programme and pitched to investors on the final day of the Accelerator programme in November 2020.
During 2020, the Oxford AHSN together with delivery partner BioCity, ran the second Oxford AHSN Accelerator programme aimed at identifying and developing innovative and sustainable solutions to proven NHS needs2 and meeting the commercial ambitions of investors.
The programme required the cohort to spend one day a week going through a series of increasingly demanding and informative development tasks, to produce a fully viable business venture. They used tools, which included Strategyzer canvases, to assist with customer discovery, global and local market access and stakeholder engagement that are specifically tailored to the healthcare and life sciences industry. Innovators were required to meet their dedicated coach, attend regular learning sessions, and were encouraged to go out and test their key assumptions on the canvases as part of their customer discovery, by talking to key stakeholders and customers and obtaining structured feedback.
The Oxford AHSN Accelerator programme has helped MetaGuideX to validate their assumptions about their customer base and refine their product offering to be more in line with clinical needs, by providing the business with access to NHS clinicians and mentors. This has given them a good understanding of how clinicians and stakeholders within the NHS can benefit from their offering.
Impact & Outcomes
MetaGuideX pitched on the final day of the accelerator programme and were awarded £50,000 of investment as in-kind support from BioCity investors.